2016
DOI: 10.1111/bjh.14080
|View full text |Cite
|
Sign up to set email alerts
|

MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
40
1
1

Year Published

2016
2016
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 48 publications
(46 citation statements)
references
References 10 publications
4
40
1
1
Order By: Relevance
“…We chose two cell lines that share genetic feature of PCNSL, namely the MDY88 L265P mutation and mutations targeting the BCR subunits CD79B (TMD8) or CD79A (OCI-Ly10) (Braggio et al, 2015; Bruno et al, 2014; Chapuy et al, 2016; Hattori et al, 2016; Nakamura et al, 2016; Vater et al, 2015). We performed 10 × 10 dose titration experiments in which various ibrutinib concentrations were combined with various concentrations of four DNA-damaging chemotherapeutic agents, four anti-folate agents and one thymidylate synthase inhibitor (Figure 1A).…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…We chose two cell lines that share genetic feature of PCNSL, namely the MDY88 L265P mutation and mutations targeting the BCR subunits CD79B (TMD8) or CD79A (OCI-Ly10) (Braggio et al, 2015; Bruno et al, 2014; Chapuy et al, 2016; Hattori et al, 2016; Nakamura et al, 2016; Vater et al, 2015). We performed 10 × 10 dose titration experiments in which various ibrutinib concentrations were combined with various concentrations of four DNA-damaging chemotherapeutic agents, four anti-folate agents and one thymidylate synthase inhibitor (Figure 1A).…”
Section: Resultsmentioning
confidence: 99%
“…First, we performed a meta-analysis of 6 published exome sequencing studies in PCNSL (Braggio et al, 2015; Bruno et al, 2014; Chapuy et al, 2016; Hattori et al, 2016; Nakamura et al, 2016; Vater et al, 2015). Overall, MYD88 L265P mutations represented 90% of all mutations affecting the MYD88 TIR domain in PCNSL.…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…18,19 We previously found that MYD88 L265P mutations had a negative impact on the clinical outcome of elderly PCNSL patients. 20 The impact of MYD88 L265P mutation should be examined for younger patients treated with the R-MPV regimen followed by consolidation rdWBRT and cytarabine.…”
Section: Discussionmentioning
confidence: 99%